Pharmaceutical company Strides Arcolab said on Friday it has inaugurated its sterile injectable facility at Compos in Rio de Janeiro, Brazil.
Pharma firm Strides Arcolab said on Monday it has acquired Chennai-based Grandix Pharmaceuticals and its subsidiary Grandix Laboratories for over Rs 98 crore (about $24 million).
Due to the developments at KV, like recall of their products, regulatory actions, filing of a series of class actions by shareholders the company has terminated the 'License and Supply Agreement', Strides Arcolab said in a filing to the Bombay Stock Exchange.
Pharmaceutical firm Strides Arcolab on Friday said it has launched its anti-swine flu drug 'Starflu'.
Strides Arcolab Ltd has signed an agreement with US-based bio-pharmaceutical company, Gilead Sciences, for manufacturing and distributing generic versions of anti-HIV drugs Truvada and Viread.
Drug firm Strides Acrolab on Tuesday said it is in a position to supply Oseltamivir Capsules, the only available medicine against Influenza A HINI virus (Swine Flu), to meet the demand both from domestic and overseas market.
Dr Reddy's Laboratories & Strides Arcolabs are at a risk of raiders as their promoter holdings are less than 26%. Promoters of Dr Reddy's have 25.15% stake as on Dec 31, 2007 and the share value of the company has dipped 19.9 per cent since January 1 this year. The Bangalore-based Strides Arcolab had only 18.82% promoter-holding as on Dec 31, 2007. The stock price of the company has gone down 34% in the same period. The promoters are taking steps to correct the situation.
Of BSE 500 companies, promoters of 142 companies have pledged their holding.
With local companies facing stress in domestic operations, valuations are down.
Rs 1,965-cr deal helps it rake in 3.5 times its investment within four years.
Torrent Pharmaceuticals' Rs 3,000 crore proposal for increasing FII investment limit to 35 per cent was the biggest in terms of value
Strides Arcolab Ltd's, US subsidiary Strides Inc and STADA Pharmaceuticals Inc, the US subsidiary of STADA Arzneimittel AG, have signed a development and supply agreement for a prescription generic drug product for the US market.
Matrix Laboratories Ltd and Strides Arcolab Ltd on Saturday said they have called off the proposed merger as the two companies were unable to reach an agreement on valuation.
Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes
As the Sensex continued with its record-breaking show, over 750 stocks hit one-year high levels on the Bombay Stock Exchange on Friday.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
IT, pharma and FMCG stocks are the top performers in 2013.
The 15 proposals were cleared following recommendations by Foreign Investment Promotion Board.
Sensex ended strong, Tata Steel, HUL climb higher.
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
The founders of Gland Pharma, led by Ravi Penmetsa, and KKR, together own 96 per cent of the company.
The winter session of Parliament will commence on November 26.
Broader market outperformed the headline indices with BSE Midcap and Smallcap finishing the day 1.22%, and 1.54% higher, respectively
The 30-share Sensex provisionally ended up 112 points at 28,555 and the 50-share Nifty closed 24 points higher at 8,561 after hitting a record high of 8,626.95.
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
Select companies in infra, capital goods, private banks, auto, oil & gas, and mining could be considered by investors.
.jpg)
Markets ended lower on profit taking ahead of June F&O expiry.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
Among the index heavyweights, Reliance Industries ended down 1.9% while mortage lender HDFC eased 0.2%. FMCG major ITC ended down 1.3%.
Major global indices like CAC 40, DAX Shanghai Composite, Hang Seng, Nikkei, Straits Times, Sensex, Nifty have lost 1% - 10% in a week
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances